Evidence map›Paper›PMID 39335568›Full record

ArticleBiomedicines2024

Predictive Model for Opioid Use Disorder in Chronic Pain: A Development and Validation Study.

Mónica Escorial, Javier Muriel, César Margarit, Laura Agulló, Thomas Zandonai, Ana Panadero, Domingo Morales, Ana M Peiró

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mónica EscorialPharmacogenetics Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Diagnostic Center, Gray Building, 5th Floor, Avda Pintor Baeza, 12, 03010 Alicante, Spain.ORCID 0000-0003-3235-1879
Javier MurielPharmacogenetics Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Diagnostic Center, Gray Building, 5th Floor, Avda Pintor Baeza, 12, 03010 Alicante, Spain.ORCID 0000-0003-0048-9451
César MargaritPain Unit, Dr. Balmis General University Hospital, ISABIAL, 03010 Alicante, Spain.ORCID 0000-0002-1854-9005
Laura AgullóPharmacogenetics Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Diagnostic Center, Gray Building, 5th Floor, Avda Pintor Baeza, 12, 03010 Alicante, Spain.ORCID 0000-0002-8739-0456
Thomas ZandonaiPharmacogenetics Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Diagnostic Center, Gray Building, 5th Floor, Avda Pintor Baeza, 12, 03010 Alicante, Spain.ORCID 0000-0002-7606-9675
Ana PanaderoPain Unit, Dr. Balmis General University Hospital, ISABIAL, 03010 Alicante, Spain.
Domingo MoralesOperations Research Center, University Miguel Hernández de Elche, 03202 Elche, Spain.ORCID 0000-0002-9794-5654
Ana M PeiróPharmacogenetics Unit, Clinical Pharmacology Department, Alicante Institute for Health and Biomedical Research (ISABIAL), Diagnostic Center, Gray Building, 5th Floor, Avda Pintor Baeza, 12, 03010 Alicante, Spain.ORCID 0000-0002-2385-3749

Funding

ALICANTE INSTITUTE FOR HEALTH AND BIOMEDICAL RESEARCH UGP 21-116NATIONAL DRUGS PLAN 2023I031NAVARRO-TRIPODI FOUNDATION 2021 Research GrantSPANISH CLINICAL PHARMACOLOGY SOCIETY 2022 Research Award
6 · The paper itself

Abstract

BACKGROUND/

objectiveThere are several questionnaires for the challenge of anticipating opioid use disorder (OUD). However, many are not specific for chronic non-cancer pain (CNCP) or have been developed in the American population, whose sociodemographic factors are very different from the Spanish population, leading to scarce translation into clinical practice. Thus, the aim of this study is to prospectively validate a predictive model for OUD in Spanish patients under long-term opioids.

methodsAn innovative two-stage predictive model was developed from retrospective (

resultsThe two-stage model comprised risk factors related to OUD (younger age, work disability and high daily opioid dose) and provided new useful information about other risk factors (low quality of life,

conclusionsOur study presents the results of an innovative model for predicting OUD in our setting. After external validation, it could represent a change in the paradigm of opioid treatment, helping clinicians to better identify and manage the risks and reduce the side effects and complications.

Indexed as

ambulatory follow-upchronic non-cancer painchronic opioid useopioid use disorderpredictive modelprevention

Identifiers

PMID39335568
PMCPMC11428664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.